dabrafenib + trametinib
ApprovedActiveDevelopment Stage
Diffuse Astrocytoma
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
Nov 4, 2019 → Nov 6, 2026
About dabrafenib + trametinib
dabrafenib + trametinib is a approved stage product being developed by Novartis for Diffuse Astrocytoma. The current trial status is active. This product is registered under clinical trial identifier NCT03975829. Target conditions include Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma.
What happened to similar drugs?
0 of 20 similar drugs in Diffuse Astrocytoma were approved
Hype Score Breakdown
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07440290 | Phase 2/3 | Recruiting |
| NCT04961619 | Pre-clinical | Completed |
| NCT04547946 | Pre-clinical | Completed |
| NCT05171374 | Pre-clinical | UNKNOWN |
| NCT04666272 | Pre-clinical | Active |
| NCT04452877 | Phase 2 | Completed |
| NCT03975829 | Approved | Active |
| NCT02672358 | Phase 2 | Withdrawn |
| NCT03551626 | Phase 3 | Completed |
| NCT02974803 | Phase 2 | Terminated |
| NCT03340506 | Approved | Recruiting |
| NCT02367859 | Phase 2 | Completed |
| NCT03091257 | Phase 1 | Active |
| NCT02083354 | Phase 2 | Completed |
| NCT02034110 | Phase 2 | Completed |
| NCT02039947 | Phase 2 | Completed |
| NCT01336634 | Phase 2 | Completed |
Competing Products
20 competing products in Diffuse Astrocytoma